FAKTOR OPTIONSSCHEIN - GENMAB | Real-time Boerse Frankfurt Warrants 10:21:03 2024-05-21 EDT | ||
| 2 EUR | -1.96% |
|
| 1 month | +0.99% | ||
| 3 months | +0.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 2 | -1.96% |
| 24-05-17 | 2.04 | 0.00% |
| 24-05-16 | 2.04 | -2.39% |
| 24-05-15 | 2.09 | +2.96% |
| 24-05-14 | 2.03 | +4.10% |
Real-time Boerse Frankfurt Warrants
Last update May 21, 2024 at 10:21 am
More quotesStatic data
| Product type | Warrant Esotici e Strutturati |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
BNP Paribas
|
| WKN | PH2GEN |
| ISIN | DE000PH2GEN1 |
| Date issued | 2020-04-16 |
| Strike | 2,041 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.3 € |
|---|---|
| Lowest since issue | 1.74 € |
| Spread | 0.01 € |
| Spread % | 0.50% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
2,041
DKK
Average target price
2,470
DKK
Spread / Average Target
+21.01%
- Stock Market
- Certificates
- Certificat
